Sanara MedTech Set to Announce Q3 Earnings on November 12

Sanara MedTech Inc. (NASDAQ: SMTI) is poised to release its third-quarter earnings for 2025 on November 12, 2025, prior to the market opening. Analysts anticipate that the company will report a loss of $0.24 per share, alongside projected revenues of $26.625 million for the quarter. Investors looking for the latest updates can follow the earnings summary page available on Sanara MedTech’s website, with the earnings call scheduled for 8:00 AM ET on the same day.

The last earnings report from Sanara MedTech was released on August 13, where the company reported a loss of $0.23 per share, surpassing the consensus estimate of $0.33 by $0.10. Revenue for that quarter reached $25.83 million, exceeding analyst expectations of $25.15 million. Despite these results, Sanara MedTech continues to face challenges, reflected in its negative net margin of 10.22% and a return on equity of -26.43%.

Analysts project that the company will close the current fiscal year with an average loss of $1 per share, with similar expectations for the following fiscal year.

Current Market Status and Analyst Opinions

On the trading front, shares of Sanara MedTech experienced a slight decline, opening at $27.72 on Monday. The company has a debt-to-equity ratio of 1.25, with a quick ratio of 2.03 and a current ratio of 2.26. Its 50-day moving average is $31.52, while the 200-day moving average stands at $30.15. The company’s market capitalization is approximately $246.71 million, with a price-to-earnings ratio of -23.90 and a beta of 1.21. Over the past year, the stock has fluctuated between a low of $23.53 and a high of $39.08.

Recent analysis from various brokerages has provided mixed opinions on the stock. On November 1, Wall Street Zen downgraded Sanara MedTech from a “buy” to a “hold” rating. Conversely, HC Wainwright raised its price target from $53.00 to $54.00, maintaining a “buy” rating in a report dated August 18. Weiss Ratings, however, restated a “sell (e+)” rating on October 8. Currently, two investment analysts have issued a “buy” rating, while one has rated the stock as a “sell.” According to data from MarketBeat.com, the consensus rating for Sanara MedTech is “hold,” with an average target price of $50.00.

Institutional Trading Activity

Recent activity among institutional investors indicates a shift in holdings for Sanara MedTech. Vanguard Group Inc. has increased its stake in the company by 3.4% during the third quarter, now owning 182,032 shares valued at approximately $5.776 million following the purchase of an additional 6,049 shares. JPMorgan Chase & Co. also boosted its stake by 26.5%, bringing its total to 11,057 shares worth $351,000 after acquiring 2,315 additional shares.

In a significant move, Lazard Asset Management LLC increased its holdings by 63,100% in the second quarter, now owning 3,160 shares valued at $89,000 after purchasing 3,155 shares. Marshall Wace LLP raised its stake by 144.3%, owning 71,511 shares worth $2.030 million following an acquisition of 42,237 shares. HSBC Holdings PLC has also entered the fray, acquiring a new position valued at $382,000 during the second quarter. Institutional investors currently hold 8.10% of the company’s stock.

Sanara MedTech focuses on developing and distributing surgical, wound, and skincare products. Its offerings include CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen tailored for managing various types of wounds and burns, and HYCOL, also a hydrolysate aimed at treating full and partial thickness wounds.

As Sanara MedTech prepares to announce its earnings, the market will be closely watching the results and any guidance provided for future performance.